
Viral Vector Process Development
Translating Discovery into Scalable, GMP-Ready Manufacturing

Minaris partners with innovators to accelerate the development of advanced therapies through fully integrated, regulatory-focused viral vectors platforms spanning viral vectors, cell therapies, and testing. With over 25 years of experience, we bring proven expertise in end-to-end viral vector capabilities.
Our process development teams are dedicated to building scalability, consistency, and compliance into every program, helping therapy developers reduce the cost of goods (COGs) and make vector-based therapies more affordable and accessible.
End-to-End Development Expertise
Our viral vector process development services span the complete pathway from early-stage research through GMP readiness:
Upstream Process Development
Cell line selection and optimization (HEK293, HEK293T, XOFLX® packaging cell line and stable cell line)
Platform- and vector-specific transfection or infection strategies
Media and feed optimization for maximum productivity
Scalable single-use bioreactor systems up to 200L for development
Downstream Process Development
Purification strategies, including clarification, chromatography and ultrafiltration/diafiltration (UF/DF)
A systematic approach to optimizing recovery, purity and potency
Scalable downstream operations with consistent product quality
Formulation Development
Comprehensive stability-focused buffer and excipient selection
Development of final drug product formulations for both early-phase and late-phase programs
Upstream Process Development
Cell line selection and optimization (HEK293, HEK293T, XOFLX® packaging cell line and stable cell line)
Platform- and vector-specific transfection or infection strategies
Media and feed optimization for maximum productivity
Scalable single-use bioreactor systems up to 200L for development
Downstream Process Development
Purification strategies, including clarification, chromatography and ultrafiltration/diafiltration (UF/DF)
A systematic approach to optimizing recovery, purity and potency
Scalable downstream operations with consistent product quality
Formulation Development
Comprehensive stability-focused buffer and excipient selection
Development of final drug product formulations for both early-phase and late-phase programs